{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:57:31Z","timestamp":1770818251331,"version":"3.50.1"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T00:00:00Z","timestamp":1397692800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1003568","type":"journal-article","created":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T20:54:02Z","timestamp":1397768042000},"page":"e1003568","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":58,"title":["Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study"],"prefix":"10.1371","volume":"10","author":[{"given":"Laetitia","family":"Canini","sequence":"first","affiliation":[]},{"given":"Jessica M.","family":"Conway","sequence":"additional","affiliation":[]},{"given":"Alan S.","family":"Perelson","sequence":"additional","affiliation":[]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2014,4,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1473-3099(09)70199-9","article-title":"Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis","volume":"9","author":"J Burch","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJM199709253371302","article-title":"Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group","volume":"337","author":"FG Hayden","year":"1997","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.282.13.1240","article-title":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment","volume":"282","author":"FG Hayden","year":"1999","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/S0264-410X(03)00075-6","article-title":"The role of antivirals in the control of influenza","volume":"21","author":"AS Monto","year":"2003","journal-title":"Vaccine"},{"key":"ref5","unstructured":"NICE (2009) Amantadine, oseltamivir and zanamivir for the treatment, Review of NICE technology appraisal guidance 58. London: National Institute for Clinical Excellence."},{"key":"ref6","unstructured":"World Health Organization (2004) WHO guidelines on the use of vaccines and antivirals during influenza pandemics. Geneva, Switzerland: [Online.] <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/csr\/resources\/publications\/influenza\/11_29_01_A.pdf\" xlink:type=\"simple\">http:\/\/www.who.int\/csr\/resources\/publications\/influenza\/11_29_01_A.pdf<\/ext-link>."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"LV Gubareva","year":"2000","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/clpt.2009.142","article-title":"Stockpiling antiviral drugs for the next influenza pandemic","volume":"86","author":"A Patel","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"b5106","DOI":"10.1136\/bmj.b5106","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis","volume":"339","author":"T Jefferson","year":"2009","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/jmv.20951","article-title":"Neuraminidase inhibitor resistance in influenza viruses","volume":"79","author":"PA Reece","year":"2007","journal-title":"J Med Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.00555-08","article-title":"Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008","volume":"52","author":"TG Sheu","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","unstructured":"World Health Organization (2009) Pandemic (H1N1) 2009 - update 67. [Online.] <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/csr\/don\/2009_09_25\/en\/index.html\" xlink:type=\"simple\">http:\/\/www.who.int\/csr\/don\/2009_09_25\/en\/index.html<\/ext-link>."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"M Kiso","year":"2004","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"RJ Whitley","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/infdis\/jiq124","article-title":"Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients\u2013North Carolina, 2009","volume":"203","author":"LF Chen","year":"2010","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3201\/eid1704.101429","article-title":"H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients","volume":"17","author":"C Renaud","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"ref17","first-page":"37","article-title":"Update on oseltamivir resistant pandemic A (H1N1) 2009 influenza virus: January 2010","volume":"85","year":"2010","journal-title":"Weekly Epidemiological Record"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1128\/JVI.01318-10","article-title":"Population modeling of influenza A\/H1N1 virus kinetics and symptom dynamics","volume":"85","author":"L Canini","year":"2011","journal-title":"J Virol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0091270008320317","article-title":"Population pharmacokinetics of oseltamivir when coadministered with probenecid","volume":"48","author":"CR Rayner","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.00588-08","article-title":"Pharmacokinetics of high-dose oseltamivir in healthy volunteers","volume":"53","author":"Y Wattanagoon","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","unstructured":"(2008) Tamiflu (R) (oseltamivir phosphate) capsules and for oral suspension. Package Insert. Foster City, California: Roche Laboratories Inc Gilead Sciences Inc."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of influenza A virus infection in humans","volume":"80","author":"P Baccam","year":"2006","journal-title":"J Virol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1098\/rsif.2009.0067","article-title":"Towards a quantitative understanding of the within-host dynamics of influenza A infections","volume":"7","author":"A Handel","year":"2010","journal-title":"J R Soc Interface"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1128\/JVI.00689-10","article-title":"Competitive fitness of oseltamivir-sensitive and-resistant highly pathogenic H5N1 influenza viruses in a ferret model","volume":"84","author":"EA Govorkova","year":"2010","journal-title":"J Virol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1128\/JVI.01658-12","article-title":"Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening","volume":"87","author":"NC Wu","year":"2013","journal-title":"J Virol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1128\/AAC.45.12.3403-3408.2001","article-title":"Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants","volume":"45","author":"LV Gubareva","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"ref27","unstructured":"Alfonsi A, Cances E, Turinici G, Di Ventura B, Huisinga W (2004) Exact simulation of hybrid stochastic and deterministic models for biochemical systems. INRIA Report No. 5435."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1371\/journal.pcbi.0030240","article-title":"Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread","volume":"3","author":"A Handel","year":"2007","journal-title":"PLoS Comput Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1098\/rstb.2001.1007","article-title":"Perspectives on antiviral use during pandemic influenza","volume":"356","author":"FG Hayden","year":"2001","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group","volume":"283","author":"JJ Treanor","year":"2000","journal-title":"JAMA"},{"key":"ref31","unstructured":"World Health Organization (2010) WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses - Part I Recommendations. [online] <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/csr\/resources\/publications\/swineflu\/h1n1_guidelines_pharmaceutical_mngt.pdf\" xlink:type=\"simple\">http:\/\/www.who.int\/csr\/resources\/publications\/swineflu\/h1n1_guidelines_pharmaceutical_mngt.pdf<\/ext-link>."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa0911530","article-title":"Comparative epidemiology of pandemic and seasonal influenza A in households","volume":"362","author":"BJ Cowling","year":"2010","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jtbi.2004.08.001","article-title":"A simple cellular automaton model for influenza A viral infections","volume":"232","author":"C Beauchemin","year":"2005","journal-title":"J Theor Biol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/jtbi.1994.1074","article-title":"Mathematical model of antiviral immune response. III. Influenza A virus infection","volume":"167","author":"GA Bocharov","year":"1994","journal-title":"J Theor Biol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jtbi.2006.12.015","article-title":"A dynamical model of human immune response to influenza A virus infection","volume":"246","author":"B Hancioglu","year":"2007","journal-title":"J Theor Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1128\/JVI.00098-09","article-title":"Simulation and prediction of the adaptive immune response to influenza A virus infection","volume":"83","author":"HY Lee","year":"2009","journal-title":"J Virol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"6687","DOI":"10.1128\/JVI.00266-10","article-title":"Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus","volume":"84","author":"H Miao","year":"2010","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"144107","DOI":"10.1063\/1.2354085","article-title":"A \u201cpartitioned leaping\u201d approach for multiscale modeling of chemical reaction dynamics","volume":"125","author":"LA Harris","year":"2006","journal-title":"J Chem Phys"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/JVI.02681-13","article-title":"Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A (H1N1) pdm09 Virus In Vitro, in Mice and in Ferrets","volume":"88","author":"Y Abed","year":"2014","journal-title":"J Virol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e1002431","DOI":"10.1371\/journal.ppat.1002431","article-title":"Role of permissive neuraminidase mutations in influenza A\/Brisbane\/59\/2007-like (H1N1) viruses","volume":"7","author":"Y Abed","year":"2011","journal-title":"PLoS Pathog"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e1003354","DOI":"10.1371\/journal.ppat.1003354","article-title":"Antigenic Drift of the Pandemic 2009 A (H1N1) Influenza Virus in a Ferret Model","volume":"9","author":"T Guarnaccia","year":"2013","journal-title":"PLoS Pathog"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/dkg007","article-title":"Early administration of oral oseltamivir increases the benefits of influenza treatment","volume":"51","author":"FY Aoki","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/cid\/cis636","article-title":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09","volume":"55","author":"JK Louie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/infdis\/jis726","article-title":"Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009\u20132010 influenza A (H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients","volume":"207","author":"SG Muthuri","year":"2013","journal-title":"J Infect Dis"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group","volume":"355","author":"KG Nicholson","year":"2000","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1128\/AAC.01339-05","article-title":"Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use","volume":"50","author":"AS Monto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1086\/318537","article-title":"Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir","volume":"183","author":"LV Gubareva","year":"2001","journal-title":"J Infect Dis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1473-3099(13)70267-6","article-title":"Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial","volume":"14","author":"AM Fry","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1137\/120876800","article-title":"Stochastic Analysis of Pre-and Postexposure Prophylaxis against HIV Infection","volume":"73","author":"JM Conway","year":"2013","journal-title":"SIAM J Appl Math"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e1001058","DOI":"10.1371\/journal.pcbi.1001058","article-title":"Stochastic theory of early viral infection: Continuous versus burst production of virions","volume":"7","author":"JE Pearson","year":"2011","journal-title":"PLoS Comput Biol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/INF.0b013e3182472f28","article-title":"Safety and Pharmacokinetics of Oseltamivir for Prophylaxis of Neonates Exposed to Influenza H1N1","volume":"31","author":"HC Maltezou","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00228-003-0639-6","article-title":"Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1\u20135 years","volume":"59","author":"C Oo","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/infdis\/jit034","article-title":"Heterogeneity in viral shedding among individuals with medically attended influenza A virus infection","volume":"207","author":"LL Lau","year":"2013","journal-title":"J Infect Dis"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/cis1220","article-title":"Global assessment of resistance to neuraminidase inhibitors, 2008\u20132011: the Influenza Resistance Information Study (IRIS)","volume":"56","author":"RJ Whitley","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1473-3099(13)70287-1","article-title":"Optimum timing of oseltamivir: lessons from Bangladesh","volume":"14","author":"MG Ison","year":"2014","journal-title":"Lancet Infect Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1003699","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,6,3]],"date-time":"2014-06-03T00:00:00Z","timestamp":1401753600000}}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1003568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T21:08:31Z","timestamp":1588972111000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1003568"}},"subtitle":[],"editor":[{"given":"Sergei L.","family":"Kosakovsky Pond","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2014,4,17]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1003568","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1003699","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,17]]}}}